Intellectual Property

U.S. Patent (12/842,773) “Methods and Compositions involving NAMPT/PBEF inhibitors for lung inflammation”, filed July 23, 2010 by University of Chicago (IAA with University of Illinois at Chicago and University of Arizona), patent issued by USPTO Aug 9, 2016.  Exclusive license on method of use issued by University of Arizona June 2017.

U.S. Patent on 9 human monoclonal Ab compositions to be filed in Q3 2017, jointly owned by Aqualung Therapeutics and Gennova Biopharmaceuticals in Pune, India.